PACS Group reports Q1 2026 results today with a notable insider selling pattern casting a shadow over the stock.
A cluster of C-suite sales in April tells the clearest story heading into the print. On April 15, the President and COO sold nearly 198,000 shares at $33.14, raising $6.5 million. The Chief Legal Officer and Chief Accounting Officer sold alongside him on the same day, adding another $3 million in combined proceeds. That follows a further sale by the COO in March at $34.28. In total, net insider sales over the 90-day window reached roughly $13.5 million — all one-directional. The stock has since slipped to $31.90, meaning those sales look better timed with every session.
The analyst community remains constructive despite the selling pressure. All four covering analysts carry buy-equivalent ratings, with a mean price target near $45 — roughly 43% above where the stock trades now. UBS and RBC both lifted targets in early March, following a Q4 print that initially pushed the stock up 4% on the day before reversing. The February earnings release was more bruising: the stock fell 7% on the day and extended that to nearly 10% over the following week. Bulls are betting that revenue near $5.7 billion and net income of $314 million in estimated annual terms justify a re-rating from current levels. Bears point to the February reaction, the relentless insider selling, and a stock that is down 12.5% year to date.
Short positioning is a minor subplot rather than the headline. SI % FF runs at just 2.7% of the free float — up about 14% over the past month but still modest in absolute terms. The borrow market reflects that: cost to borrow is well under 1% at 0.49%, and availability is ample. Days to cover on official FINRA data stand at 5.75, which means there is no structural squeeze dynamic in play. The short score of 53.7 is mid-range, pointing to no extreme directional conviction from the short-selling community.
Options positioning has nudged slightly more defensive into today's release. The put/call ratio moved to 0.12, sitting close to 1.7 standard deviations above its 20-day average — elevated relative to recent norms, though still far below the 52-week high of 1.55. The RSI at 47.8 places the stock in neutral territory technically, neither oversold nor overbought.
The print is therefore less a debate about whether PACS can grow and more about whether management can explain the gap between what insiders have been doing with their own shares and what the Street's buy ratings imply for the stock's trajectory.
See the live data behind this article on ORTEX.
Open PACS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
